Multicenter development and validation of a probability-based model to diagnose Lewy body disease using ¹²³I-meta-iodobenzylguanidine

20260 citationsJournal Articlehybrid Open Access

Authors

Kenichi Nakajima · Kanazawa University

Junji Komatsu · Kanazawa University

Takeshi Matsumura · Kanazawa University

Satoshi Orimo · National Institute of Health Sciences

Mitsuhiro Yoshita · National Hospital Organization

Viviana Frantellizzi · Sapienza University of Rome

Maria Silvia De Feo · Sapienza University of Rome

Abstract

The probability-based <sup>123</sup>I-mIBG model reliably differentiated LBD from other diseases. Standardization among sites supports global applicability and reflects real-world clinical practice.

Topics & Keywords

Parkinson's Disease Mechanisms and Treatments Dementia and Cognitive Impairment Research Epilepsy research and treatment

UN Sustainable Development Goals

Reduced inequalities

Publication Details

Published in: European Journal of Nuclear Medicine and Molecular Imaging

Volume 53, Issue 5, pp. 3481-3494

DOI: 10.1007/s00259-025-07706-0

Field-Weighted Citation Impact: 0.00